Uniphar (LON:UPR) Given “Buy” Rating at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reaffirmed their buy rating on shares of Uniphar (LON:UPR) in a report published on Wednesday, Marketbeat Ratings reports. They currently have a GBX 310 ($4.08) target price on the stock.

Uniphar Price Performance

Shares of UPR stock opened at GBX 221 ($2.91) on Wednesday. The company has a debt-to-equity ratio of 114.50, a current ratio of 0.88 and a quick ratio of 0.60. The firm’s 50-day moving average is GBX 217.21 and its two-hundred day moving average is GBX 222.39. Uniphar has a 12 month low of GBX 178 ($2.34) and a 12 month high of GBX 256 ($3.37). The company has a market capitalization of £603.37 million, a PE ratio of 1,578.57 and a beta of 0.77.

Uniphar Cuts Dividend

The company also recently announced a dividend, which will be paid on Friday, October 4th. Shareholders of record on Thursday, September 12th will be paid a dividend of €0.01 ($0.01) per share. This represents a yield of 0.25%. The ex-dividend date of this dividend is Thursday, September 12th. Uniphar’s dividend payout ratio (DPR) is presently 1,428.57%.

Uniphar Company Profile

Uniphar plc operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, The Netherlands, and internationally. The company operates through three divisions: Medtech, Pharma, and Supply Chain & Retail. The Medtech division offers outsourced sales; and marketing, distribution, and support services to medical device manufacturers.